ISTA Pharmaceuticals Announces Receipt of Subpoena Relating to Promotional Practices for Xibrom
...today reported that it has received a subpoena from the United States Attorney's Office in Buffalo requesting the production of documents regarding promotional, educational and other activities relating to Xibrom(TM) (bromfenac sodium ophthalmic solution) 0.09%. It is ISTA's policy to fully comply...

Lilly Resolves Investigations of Past Zyprexa Marketing and Promotional Practices
...Litigation of the Department of Justice regarding the previously-reported government investigation into the company's past U.S. marketing and promotional practices for the antipsychotic medication Zyprexa(R) (olanzapine). Lilly has been cooperating with the government in its investigation since...

Cephalon Concludes All Outstanding Federal and State Government Investigations into the Company's Sales and Promotional Practices
...agreements with the Attorneys General of the states of Connecticut and Massachusetts to settle related investigations into the company's sales and promotional practices. The initial investigations began in 2004 and involved three of the company's nine proprietary products in the United States -- Actiq(R)...

Allergan Comments on the United States Department of Justice Subpoena for the Production of Documents Relating to Promotional Practices of Botox for Therapeutic Uses
...States Department of Justice, United States Attorney's Office for the Northern District of Georgia requesting the production of documents regarding promotional practices involving BOTOX(R) (botulinum toxin type A) for therapeutic indications. The subpoena broadly requests documents regarding promotional,...

SDI Reports: Promotional Expenditures Flatten as the Number of Branded Blockbuster Drugs Decreases
...which peaked in 2006 at 38, receded to 34 in 2008. With fewer blockbusters to promote, it comes as no surprise that pharmaceutical manufacturers' promotional spending tapered off. Total promotional expenditures were flat in 2008, increasing only 1% (as tracked by SDI's promotional audit suite). Spending...

SDI Reports Sixty-Seven Percent of Physicians Surveyed Have Positive Attitude Toward Electronic Promotional Activities
...for the two groups to interact more regularly. Other key findings include:   Sixty-nine percent of surveyed physicians participate in electronic promotional activities after office hours, in the evenings. In 2008, the average time spent by a physician on a single ePromotion activity was 18 minutes....

Pfizer Concludes Previously Disclosed Settlement Agreement With U.S. Department Of Justice Regarding Past Promotional Practices
...finalized a previously reported agreement in principle with the U.S. Department of Justice (DOJ) to settle an investigation regarding past off-label promotional practices related to Bextra, which Pfizer voluntarily withdrew from the market in 2005. The final agreement also resolves other DOJ investigations...

SDI Reports: Sixty-Seven Percent Of Physicians Surveyed Have Positive Attitude Toward Electronic Promotional Activities
...for the two groups to interact more regularly. Other key findings include: * Sixty-nine percent of surveyed physicians participate in electronic promotional activities after office hours, in the evenings. * In 2008, the average time spent by a physician on a single ePromotion activity was 18 minutes....

Pfizer Reports Second-Quarter 2007 Results, Reconfirms Full-Year 2007 and 2008 Financial Guidance and Updates Progress on Immediate Business Priorities
...we have incorporated a moderation in the level of decline of prescriptions in the U.S. market relative to the second quarter, reflecting extensive promotional and contracting efforts. In addition, we have incorporated an increase in the level of contracting rebates consistent with our current, more...

Pfizer Reports Second-Quarter 2008 Results
...the positive impact of foreign exchange, which increased revenues by approximately $800 million or 7%, as well as the solid performance of many key products. These factors more than offset the revenue declines due to the loss of U.S. exclusivity for Zyrtec, which Pfizer ceased selling in late January...

Having trouble finding what you want?

• Try browsing our A-Z List of Drug Names or our Medical Encyclopedia.
• Try posting your query on the Drugs.com Community Discussion Boards
• Drug Interactions Checker provides detailed information on drug-drug and drug-food interactions.
• Pill Identifier will help you identify an unknown pill by imprint code or shape/color.
• Image Search is helpful if you want to know what a certain pill looks like.
• News, FDA Approvals or In The Pipeline may help if the drug you are looking for is a new drug.